Corcept Therapeutics Announces Partnership With Idis for Global Access to Korlym(R)
July 24 2013 - 9:00AM
Marketwired
Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today
that Korlym® (mifepristone) 300 mg Tablets is available to patients
outside of the United States through an Idis Access Program. Idis
Access Programs enable patients around the world to be prescribed
investigational or approved drugs prior to their commercial launch
in that country through a regulatory-compliant and ethical channel
on a named-patient basis. Corcept, a pharmaceutical company engaged
in the discovery, development and commercialization of drugs for
the treatment of severe metabolic and psychiatric disorders, has
been offering Korlym in the United States since April 2012 as a
once-daily oral treatment of hyperglycemia secondary to endogenous
Cushing's syndrome in adult patients who have type 2 diabetes
mellitus or glucose intolerance and have failed surgery or are not
candidates for surgery.
"We are pleased to partner with Idis so that physicians outside
the United States can prescribe Korlym," said Steven Lo, Corcept's
Vice President of Commercial Operations. "We are dedicated to
meeting the needs of patients worldwide. Our partnership with Idis
will help us make sure that every Cushing's syndrome patient who
could benefit from Korlym will have access to the medicine."
Charles Simmons, President of Established Brands at Idis said of
the partnership, "We are very excited to work with Corcept to
provide patients around the world with access to this important
treatment. Patients are at the heart of what we do at Idis and
providing access to an important medicine like Korlym, creating a
bridge to treatment irrespective of the number of patients
involved, is one of the ways we do it".
Licensed healthcare professionals outside the United States with
patients who might benefit from Korlym should contact Idis
directly:
Idis UK & Eire Enquiries Tel: +44 (0) 1932 824 100 Fax: +44
(0) 1932 824 300 Email: uk@idispharma.com
Idis Rest of the World Enquiries Tel: +44 (0) 1932 824 123 Fax:
+44 (0) 1932 824 323 Email: internationalsales@idispharma.com
About Cushings Syndrome Endogenous
Cushing's syndrome is caused by prolonged exposure of the body's
tissues to high levels of the hormone cortisol and is generated by
tumors that produce cortisol or ACTH. Cushing's syndrome is an
orphan indication that most commonly affects adults aged 20 to 50.
Symptoms vary, but most people have one or more of the following
manifestations: high blood sugar, diabetes, high blood pressure,
upper body obesity, rounded face, increased fat around the neck,
thinning arms and legs, severe fatigue and weak muscles.
Irritability, anxiety, cognitive disturbances and depression are
also common. Cushing's syndrome can affect every organ system in
the body and can be fatal if not treated effectively.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery,
development and commercialization of drugs for the treatment of
severe metabolic and psychiatric disorders. Korlym, a first
generation GR-II antagonist, is the company's first FDA-approved
medication. Corcept has a phase 3 trial underway for mifepristone
for treatment of the psychotic features of psychotic depression and
a portfolio of selective GR-II antagonists that block the effects
of cortisol but not progesterone. It owns extensive intellectual
property covering the use of GR-II antagonists, including
mifepristone, in the treatment of a wide variety of metabolic and
psychiatric disorders. It also holds composition of matter patents
for its selective GR-II antagonists. For more information about
Corcept please visit: www.corcept.com
About Idis Idis has 25 years experience
partnering with pharmaceutical and biotechnology companies to
create regulatory-compliant, ethical access to medicines for
healthcare professionals and their patients with unmet medical
needs. Since 1987, Idis has developed and managed access to
thousands of medicines from every therapeutic category, impacting
the lives of hundreds of thousands of patients in countries around
the world.
Idis leverages decades of experience, regulatory insight, and a
thorough understanding of local and global requirements to create
access to medicines at every stage of a product's lifecycle from
pre-approval to market exit, and in times of unexpected production
shortages.
The company's European headquarters are located in Weybridge,
United Kingdom, and North American headquarters are located in
Princeton, NJ.
For more information about Idis please visit
www.idispharma.com.
Contact: Charles Robb Chief Financial Officer Phone:
650-688-8783 Email: Email Contact www.corcept.com Contact:
Angela Norton Phone: +44 7814 460301 Email: Email Contact
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024